Mirati Therapeutics Receivables

Mirati Therapeutics (MRTX) currently reports a receivables of $20M as of September 2023. That compares with $9.1M in the prior-year period — up 121.4% year over year. Use the charts on this page to explore Mirati Therapeutics's receivables history and peer comparisons.

Mirati Therapeutics's receivables increased from $9.1M to $20M — a 121.4% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mirati Therapeutics reported $20M in receivables as of September 2023. That compares with $9.1M in the prior-year period — up 121.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Mirati Therapeutics, and consider following MRTX for alerts when major investors trade the stock.

Mirati Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRTX with unrelated industries.